GI Flashcards
Treatment of locally advanced esophageal cancer
Neoadjuvant chemoradiation with carbo and paclitaxel (no traztuzumab)
Second line therapy for metastatic esophageal cancer
Ramucirumab
First line therapy for metastatic esophageal cancer
FOLFOX+/- Traztuzumab
Risk factors for adenocarcinoma of esophagus (3)
Obesity, Barret’s, GERD
Risk factors for squamous cell carcinoma of esophagus
Smoking, alcohol, ionizing radiation
Treatment of local esophageal cancer in poor surgical candidate
Endoscopic mucosal resection
Gene for hereditary diffuse gastric cancer
CDH1
Management of hereditary diffuse gastric cancer
prophylatic gastrectomy
Management of resectable gastric cancer (2)
Neoadjuvant ECF
Adjuvant 5FU + radiation
Treatment of HER2 mutated metastatic gastric cancer
trastuzumab + cisplatin/5FU
Treatment of HER2- metastatic gastric cancer
ECF or FOLFOX
Second line treatment of metastatic gastric cancer
ramcirumab+paclitaxel
HNPCC genes (3)
MSH2
MSH6
PMS2
FAP gene
APC
Cowden syndrome gene
PTEN
Gene with resistance to anti-EGFR therapy
NRAS or KRAS
Surgical approach for rectal tumor in distal one third of recturm
Abdominoperineal resection (APR)
Surgical approach for proximal two thirds of the rectum
Low anterior resection (LAR)
Adjuvant CRC treatment
FOLFOX
Treatment of resectable rectal cancer
chemoradiation -> surgery -> adjuvant chemo
Treatment of metastatic RAS WT CRC left sided
FOLFOXIRI (or FOLFOX) + cetuximab/panitumumab
Treatment of metastatic RAS mt CRC right sided
FOLFOXIRI (or FOLFOX) = bevacizumab
Adjuvant pancreatic cancer Tx in fit patients
FOLFIRINOX
Adjuvant pancreatic cancer in unfit patients
Gem/Cis
EpCAM mutation disorder
Indirectly causes Lynch
Mutation associated with 5FU toxicity
DPYD
Other tumors associated with FAP (2)
Desmoid tumors
Duodenal adenoma
TACE vs RFA for HCC
TACE for larger tumors (>4cm), RFA for smaller
Initial treatment for SCC anal cancer
CRT with 5-FU and mitomycin c
When to assess response after first line CRT in anal cancer
26 weeks
Treatment locoregional failure in rectal cancer
Surgery (APR)
First line treatment for metastatic rectal cancer
Cisplastin + 5FU
Adjuvant therapy for pancreatic cancer
Gem+capcitabine or FOLFIRINOX
Neoadjuvant therapy for pancreatic cancer
FOLFIRINOX
Chemotherapy for metastatic biliary cancer
Gem+cis
Imaging findings for HCC (arterial, venous, and delayed phase findings)
Arterial: increased
Venous: decreased
Delayed: persistent washout
